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The profoundly elevated concentrations of low-density lipoproteins (LDL) present in homozygous familial 
hypercholesterolemia lead to symptomatic cardiovascular disease and death by early adulthood. Studies 
conducted in nonhepatic tissues demonstrated defective cellular recognition and metabolism of LDL in these 
patients. Since mammalian liver removes at least half of the LDL in the circulation, the metabolism of LDL 
by cultured hepatocytes isolated from familial hypercholesterolemic homozygotes was compared to hepato-
cytes from normal individuals. Fibroblast studies demonstrated that the familial hypercholesterolemic 
subjects studied were LDL receptor-negative (less than 1% normal receptor activity) and LDL receptor-de-
fective (18% normal receptor activity). Cholesterol-depleted hepatocytes from normal subjects bound and 
internalized 125I-labeled LDL (Bmax = 2.2 p.g LDL/mg cell protein). Preincubation of normal hepatocytes 
with 200 I'g/ml LDL reduced binding and internalization by approx. 40%. In contrast, 125I_labeled LDL 
binding and internalization by receptor-negative familial hypercholesterolemic hepatocytes was unaffected 
by cholesterol loading and considerably lower than normal. This residual LDL uptake could not be ascribed 
to fluid phase endocytosis as determined by \14C]sucrose uptake. The residual LDL binding by familial 
hyper~olesterolemia hepatocytes led to a small increase in hepatocyte cholesterol content which was 
relatively ineffective in red,ucing hepatocyte 3-hydroxy-3-methylglutaryl-CoA reductase activity. Receptor-
defective familial hypercholesterolemia hepatocytes retained some degree of regulatable 125 I-labeled LDL 
uptake, but LDL uptake did not lead to normal hepatocyte cholesterol content or 3-hydroxy-3-methyl-
glutaryl-CoA reductase activity. These combined results indicate that the LDL receptor abnormality present 
in familial hypercholesterolemia fibroblasts reflects deranged hepatocyte LDL recognition and metabolism. 
In addition, a low-affinity, nonsaturable uptake process for LDL is present in human liver which does not 
efficiently modulate hepatocyte cholesterol content or synthesis. 
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Introduction 
The delivery of cholesterol to cells by the low-
density lipoproteins (LOL) through a receptor-
mediated pathway was first described a decade 
ago [1]. Fibroblasts grown from patients homo-
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zygous for familial hypercholesterolemia, an auto-
somal codominant disorder manifesting LOL 
cholesterol concentration greater than 500 mg/d] 
and accelerated atherosclerosis [2], demonstrate 
functional defects in this LDL receptor pathway 
[3-5]. Therefore, a disruption in the LOL receptor 
function as demonstrated in nonhepatic tissues 
correlated with markedly deranged lipoprotein 
metabolism. 
Since the liver is the principal organ for 
cholesterol synthesis and excretion [6), as well as 
lipoprotein production and catabolism [7], the field 
of hepatic lipoprotein receptors has been an active 
area of investigation. Receptors recognizing LOL 
(the apolipoprotein B,E receptor) have been iden-
tified in the liver of a variety of animals including 
rats [8-10), puppies [11-13], rabbits [14,15] and 
swine [16,17]. In contrast to early reports which 
indicated that human liver demonstrated few, if 
any, LOL receptors, recent studies performed with 
fresh human hepatic membranes indicate that a 
receptor for LOL is present in the human liver 
[18,19]. 
In studies conducted in patients homozygous 
for familial hypercholesterolemia, the ability of 
hepatic membranes to bind radiolabeled LOL is 
markedly reduced but not totally absent [19]. Al-
though the observed reduction in LOL-hepatic 
membrane interaction paralleled the defect ob-
served in nonhepatic tissues, the physiologic and 
pathophysiologic impact of this residual binding 
has not been previously determined. Utilizing 
newly developed techniques, the in vitro LOL 
metabolism of hepatocytes from normal and ho-
mozygous familial hypercholesterolemia subjects 
was directly evaluated. 
Methods 
Patients 
Neither patients 1 or 2 have been previously 
reported in the literature. Patient 1 was a 5-year-
old Hispanic female who presented at age 2 years 
with inderdigital and Achilles tendon xanthomas, 
Her total plasma cholesterol concentration had 
always been in excess of 700 mg/dl and both of 
her parents had Type II hyperlipoproteinemia. 
Because a variety of therapeutic regimens - in-
cluding cholestyramine, niacin, probucol, D-
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thyroxine, and fenafibrate - had not successfully 
reduced her total and LOL cholesterol concentra-
tions, a portacaval anastomosis was performed at 
the University of Pittsburgh. 
Patient 2 was a 12-year-old white female di-
agnosed as an familial hypercholesterolemia ho-
mozygote based on family history, tendon and 
tuberous xanthomas and total plasma cholesterol 
concentration in excess of 600 mg/dl. Although 
rigid adherence to bile acid sequestrant therapy 
reduced her plasma cholesterol levels, the side 
effects of drug therapy led to noncompliance and 
the patient underwent portacaval shunt. 
Lipoprotein preparation 
Plasma was obtained from normolipidernic in-
dividuals and an apolipoprotein E-deficient pa-
tien t [20] by plasmapheresis, and LO L (d = 
1.030-1.050 g/ml) was isolated by preparative 
ultracentrifugation [21]. LOL was radiolabeled by 
the iodine monochloride method [22) as modified 
for lipoproteins [23]. Labeling efficiency ranged 
from 22 to 38% and less than 3% of the label 
remained in the organic phase of a chloroform/ 
methanol (2: 1, v Iv) extraction. All LOL mass 
determinations were based on LDL protein 
concentrations assessed by the method of Lowry 
et al. [24]. Specific activities for 125I-labeled LDL 
ranged from 3.2 to 4.6 Bq/mg LDL protein. 
Cell culture techniques 
Human skin fibroblasts were derived from skin 
biopsies of normolipidernic individuals and pa-
tients 1 and 2 and maintained as previously de-
scribed [19]. 
The Human Experimentation Committee of the 
University of Pittsburgh School of medicine ap-
proved the use of hepatic biopsies obtained at the 
time of surgery for research purposes. Hepatic 
biopsies and hepatocyte isolation were undertaken 
after informed consent had been obtained. 
Hepatocytes were removed from the biopsies by 
sterile mincing of the tissue followed by col-
lagenase-hyaluronidase-dispase treatment as previ-
ously described [25]. Briefly, biopsies (1-4 g) were 
immediately perfused by subcapsular injection of 
15 ml Ca2 +-free Hanks' balanced salt solution 
supplemented with insulin (10 ,Ug/ml) and hydro-
cortisone (10- 6 M) and gassed with 5% CO2/95% 
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O2 (pH 7.4) (digestion medium) at 4°e. After 
transport to the laboratory, the specimen was 
placed in S ml cold Ca2 +-free digestion medium, 
dissected free of connective tissue and minced 
with crossed scalpels to 1 mm3 fragments. The 
mince was washed twice with cold medium and 
then placed in a 2S0-ml conical flask in 10 ml 
Ca2+-free medium at 37°e. The flask was agitated 
at 60 rpm at 37°C with continuous oxygenation 
by 5% COj95% O2 bubbling throughout the iso-
lation procedure. The pH was monitored by the 
phenol red indicator and maintained at approxi-
mately pH 7.4 by titration with 1 N NaOH. After 
15 min, the tissue fragments were allowed to settle 
and the medium was gently drawn off and re-
placed. After a second IS-min incubation, the 
medium was replaced with digestion medium plus 
5 mM CaCI 2 , 0.05% collagenase (Sigma type IV or 
Worthington type II) and 0.1% hyaluronidase 
(Sigma type 1-S). After 30 min, fresh enzyme 
solution was added. After 30 more minutes the 
medium was replaced with digestion medium with 
5 mM CaCI 2 , 0.05% collagenase and 0.05% dis-
pase. Three 30-min incubations were performed 
with this solution. Exhausted enzyme solution from 
each digestion was examined for viable hepato-
cytes which began to appear in small numbers in 
the last two collagenase-dispase digestions. After 
enzyme digestion, the tissue fragments were placed 
in a petri dish lined with sterile Nylon mesh (100 
p,m). Cold culture medium supplemented with 10% 
fetal calf serum, insulin (10 /-Lg/ml) and hydrocor-
tisone (10- 6 M) was poured over the tissue which 
was then gently dispersed with the plunger of a 12 
cm3 syringe. The remaining debris was centrifuged 
at 50 X g for 3 min. Sedimented cells were sus-
pended in fresh medium and sedimented three 
times at 20 x g for 2 min. The resulting cell pre-
paration was examined for viability by Trypan 
blue exclusion (final concentration 0.2%). Cell were 
suspended in culture medium and plated in 24-well 
Primaria tissue culture dishes at a density of 105 
cells/cm2 (2· 10 5 cells per well). 
The cells were cultured in a humidified 5% 
CO2/95% air incubator at 37°e. After 24 h, the 
medium was changed to S% fetal calf serum 
medium plus the co'mponents of serum-free 
medium (Table 1). At 72 h. the medium was 
replaced with serum-free medium. Thereafter. the 
TABLE I 
SERUM· FREE MEDIUM FOR CELL CULTURE 
Components were added to RPMI-1640 to achieve the indi-
cated final concentration components stored in sterile aliquots 
and the serum-free medium was prepared and used daily. 
Components 
Insulin 
Glucagon 
Somatotropin 
Prolactin 
Hydrocortisone 
Epidermal growth factor 
Linoleic acid/bovine serum 
albumin 
Thyrotropin releasing factor 
Glutamine 
CuS04 
ZnC1 2 
Selinous acid (N a) 
Penicillin 
Fungizone 
Streptomycin 
Final concentration 
10 /lg/ml 
10/lg/ml 
1 I'g/m! 
100 ng/ml 
106 M 
50 ng/mt 
5/lg/ml per 
0.5 mg per ml 
106 M 
1 mljl00 cm] 
10- 7 M 
10- 10 M 
10- 7 M 
100 U/ml 
0.25/lg/ml 
100 /Lg/ml 
medium was replaced at least every 48 h with 
freshly prepared serum-free medium. 
Hepatocyte albumin synthesis 
Albumin synthesis of hepatocytes was studied 
by incorporation of [3H]leucine into albumin. 
Hepatocytes in serum-free medium were washed 
with leucine-free RPMI-1640 twice. Complete 
leucine-free serum-free medium with 1 /-LCi of 
eH]leucine was then added to the well and the 
cells were incubated for 16 h. The medium was 
harvested and dialyzed extensively against phos-
phate-buffered saline/O.Ol % EDTA at 4°e. The 
amount of label incorporated into protein was 
determined by 10% trichloroacetic acid precipita-
tion. Protein content was determined by the 
method of Lowry et al. [24]. An aliquot containing 
50 }lg of protein was lyophilized, reconstituted in 
50 p,l of 0.5% SDS/O.OS M Tris-HC! (pH 8.2), and 
heated in an oil bath at 1000 e for 3 min. The 0.2 
M Tris and distilled water were added to adjust 
the final concentrations to 0.05 M Tris and 0.1 % 
SDS. Bromophenol blue tracking dye and one 
drop of glycerol were added and the samples were 
then applied to 1.5 mm polyacrylamide gels (3% 
stacking gel) in 0.38S M Tris-HCljO.1 % SDS (pH 
8.8) and electrophoresed at 5 rnA per gel overnight 
with 0.05 !vf Tris-HCljO.384 M glycine/0.1 % SDS 
(pH 8.3). Bio-Rad protein standards were in-
cluded in each analysis. The gels were fixed in 
12.5% trichloroacetic acid, stained in 0.05% 
Coomassie blue G-250 in 12.5% trichloroacetic 
acid. and destained in 5% acetic acid. Each 10-cm 
lane was cut into 2-mm slices which were placed 
in scintillation vials. Aliquots (0.5 ml) of 30% 
H 20 1 were added, the vials heated for 4 h at 80°C 
and 10 ml Aquasol II scintillation fluid added for 
radioactivi ty quantitation. Regions of radioactiv-
ity corresponding to newly synthesized protein 
were compared to the molecular weight of known 
protein standards. 
The rate of albumin synthesis was determined 
by immunoprecipitation of albumin in celllysates 
after a [3 H]leucine pulse-chase. Hepatocytes in 
serum-free medium were washed twice with 
leucine-free RPMI-1640 and then pulsed for 30 
min with leucine-free RPMI-1640 with 1 /lCi 
[3H]leucine (New England Nuclear, Boston, MA). 
The medium was removed, the cells were washed 
twice with complete RPMI-1640, and finally the 
cells were incubated for an additional 60 min with 
RPMI-1640. The medium was harvested and 
cooled on ice. The cells were washed three times 
with cold phosphate-buffered saline and lysed with 
0.25 ml phosphate-buffered saline-l % Triton X-
100. The lysate was centrifuged at 5000 X g for 1 
min. The medium and lysate supernatant were 
used for immunoprecipitation by mixing 50 /ll 
with 100 /ll unlabeled human albumin carrier (0.1 
mg/ml in 50 mM Tris, 150 mM NaCl 5 mM 
EDTA) followed by 50 /ll anti-human albumin 
(Sigma A-1I51). After mixing and incubation (18 
h) at 4°C, the precipitates were harvested by 
centrifugation at 5000 X g for 1 min with two 
washes in the Tris buffer. The radioactivity in the 
precipitate was quantitated and expressed as dpm 
per mg cell protein. 
Hepotic membrane studies 
Hepatic membranes were isolated from 1-2 g 
of hepatic tissue from normal and homozygous 
familial hypercholesterolemia patients, and the 
ability of normal and homozygous familial hyper-
cholesterolemia hepatic membranes to bind 125 1_ 
labeled LDL was assessed as outlined previously 
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[19]. Binding is expressed as ng 115I-labeled LDL 
per mg hepatic membrane binding and represents 
the mean of triplicate assays. Control and familial 
hypercholesterolemia membranes were studied at 
the same time under identical conditions. 
Cellular lipoprotein-binding studies 
Fibroblast and hepatocyte 125 I-labeled LDL-
binding assays were conducted identically, utiliz-
ing LDL isolated from a patient with 
apolipoprotein E deficiency [20]. From 0.5 to 5 . 
1Q5 cells were incubated for 24 h in 2 cm2 wells 
containing 1 ml serum-free medium. After a fur-
ther 24 h in either fresh serum-free medium or 
serum-free medium containing 200 p.g LDL pro-
tein/m!, cells were incubated with 0.5 m! of the 
indicated concentrations of 1251_!abeled LDL pro-
tein. The media from these cells were then 
harvested after 6 h, and the cells were washed with 
six I-ml ice-cold phosphate-buffered saline 
aliquots. Cells were solubilized in 1 N NaOH, 
after which the cell-associated radioactivity (bound 
and internalized) was quantitated and the cellular 
protein determined by the method of Lowry et al. 
[24]. Specifically bound and internalized 125 1_ 
labeled LDL was defined as the difference in 
binding obtained in the absence and presence of 
lO-fold excess unlabeled LDL. The harvested 
medium was used to assess the degree of 125 1_ 
labeled LDL which was degraded. After trichloro-
acetic acid precipitation of the medium using 
bovine serum albumin carrier (5 mg/ml), free 
iodine and iodine bound to tyrosine were sub-
jected to potassium iodide/H 20 2 treatment fol-
lowed by chloroform extraction as reported by 
Goldstein and Brown [1]. The radioactivity of 
aliquots of the aqueous phase was quantitated and 
the amount of degraded 125I-Iabeled LDL was 
normalized to the cellular protein content. In 
parallel dishes, fluid phase endocytosis was 
quantitated by [14C]sucrose uptake [25]. 
Morphological studies 
The light microscopic appearance of the cells in 
culture was monitored by phase-contrast mi-
croscopy. Documentation was obtained by micro-
graphs taken on Polaroid Type 55 PIN 4 x 5" 
sheet film. Original magnifications were 100 X or 
250 x. 
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Cells for ultrastructural examination were 
harvested from 25-mm2 culture dishes after fixa-
tion in equal volumes of conditioned medium and 
2.5% glutaraldehyde in 0.1 M phosphate buffer 
(pH 7.4) for a minimum of 2 h. Cells were 
harvested either within a day of plating (for analy-
sis of the primary culture cell population) or after 
7 days in culture (for analysis of the cell popula-
tion on which the functional studies were per-
formed). 
These cells were pelleted in l.S-ml conical 
centrifuge tubes, dehydrated and embedded in 100 
nm sections were stained with uranyl acetate and 
lead citrate and examined in an electron micro-
sope, where a minimum of a hundred cells was 
examined and photographed from each patient at 
each time point. 
Other assays 
Cellular cholesterol content was determined by 
an enzymic, fluorimetric assay as previously de-
scribed [19,28]. The 3-hydroxy-3-methylglutaryl-
CoA reductase activity was determined by the 
production of mevalonate [29] and normalized to 
cellular protein content [24]. Plasma lipid con-
centrations were determined using enzymic, col-
orimetric assays [30,31]. Lipoprotein concentra-
tions were derived utilizing the methods of the 
Lipid Research Clinics [32] except that HDL 
cholesterol concentrations were assessed after de-
xtran-sulfate precipitation [33]. Acylcholester-
01 : acyltransferase activity was determined in skin 
fibroblast culture [34]. 
Results 
The plasma lipid and lipoprotein concentra-
tions in the homozygous familial hypercholestero-
lemia patients were characteristic for this condi-
tion (Table II). Both the total and LDL cholesterol 
concentrations were 4-8-fold higher than the 90th 
percentile level for this age group established by 
the Lipid Research Clinics [35]. The increased 
VLDL cholesterol concentration in combination 
with the elevated LDL cholesterol levels indicated 
a Type lib phenotype. In addition, the HDL 
cholesterol concentrations were depressed. There-
fore, both study subjects manifested profoundly 
derzmged lipoprotein metabolism as reflected in 
the fasting lipoprotein concentrations. 
The markedly abnormal lipoprotein concentra-
tions observed in these familial hypercholestero-
lemia homozygotes were paralleled by the inability 
of cultured skin fibroblasts from these patients to 
metabolize LDL (Fig. 1). Normal fibroblasts 
(panel A) bound and internalized 125I-labeled LDL 
after cholesterol depletion. The cell-associated 
125I-labeled LDL was reduced by preincubating 
the cells with 200 j.tg LDL protein/m!. The LDL 
metabolism of the skin fibroblasts in patient 1 
(panel B) and in patient 2 (panel C) differed from 
normal fibroblast LDL metabolism. The fibro-
blasts of patient 1 demonstrated absolutely no 
cell-associated LDL binding and internalization. 
Although the fibroblasts of patient 2 did demon-
strate some regulatable 125I-labeled LDL binding 
and internalization, the degree of binding was less 
than 50% that of normal fibroblasts. 
Utilizing the ability of LDL cholesterol to 
stimulate the activity of the intracellular enzyme 
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Fig. 1. 12SI_labeled LDL binding and internalization by 
fibroblasts from normal and homozygous familial hyper· 
cholesterolemia patients. 5-7 ·lOs fibroblasts per 2 crn2 well 
were incubated for 48 h in serum-free medium (e) or for 24 h 
in serum-free medium with 200 ILg LDL protein/ml (O). After 
a 6-h, 37°C incubation with the indicated concentrations of 
125I-labeled LDL, cells were washed six times with ice-cold 
phosphate-buffered saline (pH 7.0). Protein and radioactivity 
determinations were performed on cells solubilized with 1 N 
NaOH. Values represent specifically bound and internalized 
125I-labeled LDL defined as the difference in binding observed 
in the absence and presence of lO-fold excess of unlabeled 
LDL. Normal fibroblasts (panel A) and fibroblasts from pa-
tient 1 (panel B) and patient 2 (ranel C) were evaluated. 
-----~----------
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TABLE II 
PLASMA LIPID AND LIPOPROTEIN CONCENTRATIONS IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 
Value;, are the means±S.E. of triplicate samples obtained in pauents 1 and 2 off all medication. LRC normals represent the 10th and 
90th percentile for girls ages 0-14 in the Lipid Research Clinical North American Prevalence Study [33J. 
Cholesterol (mg/dl) 
Total VLDL 
Patient 1 950± 59 95± 17 
Patient 2 729±45 72± 14 
LRC normals 119-190 5- 21 
acylcholesterol : acyltransferase, the fibroblast 
LDL receptor activity was quantitated. Fibro-
blasts from patient 1 demonstrated less than 1% 
normal LDL receptor activity and patient 2's 
fibroblasts had 18% normal activity. Therefore, 
these individuals reflect the variability of the de-
gree of the loss of LDL receptor activity in homo-
zygous familial hypercholesterolemia [4,5,34] and 
can be classified as receptor-negative (patient 1) 
and receptor-defective (patient 2). 
The loss of normal LDL receptor function in 
cultured fibroblasts of familial hypercholestero-
lemia subjects has been demonstrated to parallel 
reduced LDL binding to hepatic membranes from 
familial hypercholesterolemia patients [19). The 
binding of WI-labeled LDL to hepatic mem-
branes from patients 1 and 2 was compared to 
that observed in normal hepatic membranes (Ta-
ble III). Total and specific 125I-labeled LDL bind-
ing was reduced from 18-40% in the familial 
hypercholesterolemia homozygotes. In contrast, 
the nonspecific binding was comparable to that 
observed in normal membranes. Since the coeffi-
TABLE III 
Triacylglycerol 
LDL HDL (mg/dl) 
844±49 21±1 141 ± 21 
600± 50 26±8 133 ± 17 
60-120 35-70 38 ± 114 
cient of vanatlOn for the specific binding of a 
single membrane preparation was less than 3%, 
these reductions in specific binding to the mem-
branes are significant and support previous stud-
ies [18,19). In addition, just as in the fibroblast 
studies, the hepatic membranes from patient 1 
demonstrated an even greater defect in LDL re-
cognition than was observed in patient 2. There-
fore, the defective fibroblast LDL metabolism in 
these patients was associated with reduced LDL 
binding to hepatic membranes. 
In order to evaluate the role that the reduced 
hepatic membrane LDL binding might play in 
homozygous familial hypercholesterolemia hepa-
tocyte lipoprotein metabolism, hepatocytes from 
both study subjects and from normolipidemic sub-
jects were isolated and cultured in vitro. 
Morphologic studies 
Cells from both patient 1 (Fig. 2, left panel) 
and 2 (Fig. 2, right panel) taken within a day of 
harvest were unmistakably hepatocytic. Fewer than 
3% of the cell population in either patient were 
THE BINDING OF 12sI_LABELED LDL TO HEPATIC MEMBRANES FROM NORMAL AND HOMOZYGOUS FAMILIAL 
HYPERCHOLESTEROLEMIA SUBJECTS 
Hepatic membranes (56-144 p.g protein) were incubated at 37°C for 30 min with 10 p.g 125I-Iabeled LDL in the absence (total) and 
presence (nonspecific) of 20-fold excess unlabeled LDL. Values for the normal membranes represent the mean ± S.E. 
Binding (ng/mg membrane protein) 
total (% normal) nonspecific (% normal) specific (% normal) 
Normal (n = 3) 17S7±88 78±66 975 ± 100 
Patient 1 1440 (82%) 853 (109%) 588 (60%) 
Patient 2 1391 (79%) 684 (87%) 707 (73%) 
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Fig. 2. Typical cells initially isolated from patient 1 (left panel) and patient 2 (right panel) demonstrate the electron microscopic 
characteristics of hepatocytes. 
nonhepatocytic determined by counting 300-400 
cells; no fibroblasts were identified by either 
phase-contrast or electron microscopy. By electron 
microscopy, cells were characteristically rounded 
with short microvilli, identical to those normally 
identified within the space of Disse. Cell organelle 
content was typical of hepatocytes, with a pre-
ponderance of rough endoplasmic recitulum, 
mitochondria, and lipid droplets. In addition, 
lysosomes were readily identified, and occasional, 
highly characteristic peroxisomes were found. 
These findings, present in over 97% of the cells, 
provide irrefutable evidence for hepatocytic origin 
o f the vas t maj o rity o f the cells origina lly placed 
into culture. 
After 7 days in culture. the light and low mag-
nification ultrast ructural appearance of the cul-
tured cells was somewhat altered. Cells were gen-
erally larger and more adherent (Fig. 3). ye t de-
tailed ultrastructural examination revealed the 
same organelles noted originally . Specificially, 
parallel arrays of rough endoplasmic reticulum, 
often forming concen tric whorls wi th glycogen 
particles, as well as large numbers of mitochondna 
and lipid droplets, provided unmistakable evi-
dence for the persistence of hepatocytes in culture 
(Fig. 3, left panel). These findings are inconsisten t 
with fibroblasts in culture. An additional feature 
(not i!lustra ted) was the appearance of gland or 
duct lumina with junctional complexes , which ap-
peared to be intercellular bile canaliculi. In ad-
di tion, bundles of keratin filaments were seen, 
often terminating in membrane den sities resem-
bling ill-formed desmosomes. These features offer 
further evidence of the hepa tocytic origin of these 
cells and are never observed in fi broblast s in 
culture. Therefore. the biochemi ca l s tudies per-
formed on liver biopsy samples renee ted hepato-
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Fig. 3. After 7 days in tissue culture, hepatocytes adhered to the tissue culture plates, flattened out and increased in size as shown by 
phase-contrast microscopy (left panel). The elaboration of cellular lipid, rough endoplasmic reticulum and mitochondria were 
observed by electron microscopy (right panel) . 
cellular lipid and lipoprotein metabolism. 
Both normal and familial hypercholesterolemia 
cells continuously synthesized albumin for up to 7 
days. Utilizing the incorporation of ["H]ieucine 
into immunoprecipi table albumin. the 4245 i ± 
2761 dpm/ rng cell protein precipitated on day 3 
was virtually identical to the 41 660 ± 1 660 
dpm/ mg cell protein precipitated on day 7 in 
normal cells. Albumin synthesis was also observed 
in hepatocytes from patients 1 and 2 which were 
respectively 88% and 108% normal. Therefore, the 
Cultured cells were characlerized as hepatocYles by' 
morphologic as well as biochemical characteriSlics. 
Normal human hepatocytes have been shown to 
remain viable in vitro for 17 days (25]. 
The ability of normal and homozygous familial 
hypercholesterolemia hepatocytes to bind and in-
ternalize t25 I-labeled LDL was determined after 
5-6 days in tissue culture (Fig. 4). After a 48-h 
incubation in cholesterol-free familial hyper-
cholesterolemia, normal hepatocytes (panel A) 
sa turably bound LDL. Preincubation of hepato-
cytes reduced the degree of cell-associated t251_ 
labeled LDL by at least 30%. Panel A represents 
the mean values obtained from four different hu-
man hepatocyte cell lines with an interassay varia-
bility of 6-14%. Hepatocytes from both patient 1 
(panel B) and patient 2 (panel C) bound less 
125 I-labeled LDL than normal. Although patient 1 
demonstrated no apparent up-regulation of 125 1_ 
labeled LDL binding with cholesterol depletion, 
patient 2 did manifest the ability to enhance 125 1_ 
labeled LDL binding. 
This LDL-cell inleraction could not be ascribed 
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Fig. 4. 12SI_Iabeled LDL binding and internalization by 
hepatocytes from normal and homozygous familial hyper-
cholesterolemia patients. Hepatocytes (2-3.10 5 jwell) were in-
cubated for 48 h in serum-free medium. After a further 24 h in 
either serum-free medium ce) of serum-free medium containing 
200 p.g LDL protein/ml (0), hepatocytes from normal (panel 
A), patient 1 (panel B) and patient 2 (panel 2) were incubated 
at 37°C with the indicated concentration of 11SI-labeled LDL. 
After 6 h, the cells were washed six times with ice-cold phos-
phate-buffered saline (pH 7.0) and solubilized with 1 N NaOH. 
Total cell-associated binding and binding in the presence of 
10-fold excess of unlabeled LDL (nonspecific binding, .... ) is 
shown. Normal values represent the mean ± S.E. for five differ-
ent. hepatocyte preparations. 
TABLE IV 
to fluid phase endocytosis. In companion experi-
ments in which hepatocytes were handled identi-
cally, the rate of fluid phase endocytosis was 
determined using [14C]sucrose. The observed fluid 
phase endocytic rate of 0.17-0.24 ,ul medium/mg 
cell protein per 6 h of 37°C incubation could 
account for less than 5% of the observed binding. 
Therefore, not only are the differences in LOL 
metabolism present in fibroblasts of receptor-
negative and recepwr-defective familial hyper-
cholesterolemia homozygotes also seen in hepato-
cyte LDL uptake, but also the residual association 
is dependent on a process( es) other than fluid 
phase endocytosis. 
The altered LDL binding in familial hyper-
cholesterolemia hepatocytes led to abnormal cellu-
lar cholesterol homeostasis. In normal hepatocytes 
incubated in cholesterol-free medium, addition of 
LDL to the culture medium increased total and 
free cholesterol by 70% and 35%, respectively, and 
the initial esterified cholesterol content went from 
2% to 12% of the total cellular cholesterol (Table 
IV). Familial hypercholesterolemia hepatocytes in-
cubated in cholesterol-free medium contained sig-
nificant quantities of cholesterol in the esterified 
form and, in contrast to normal hepatocytes, ex-
posure of familial hypercholesterolemia to LOL 
increased total and free cholesterol only 21 % and 
29%, respectively. Furthermore, the total and free 
cholesterol content in familial hypercholestero-
CHOLESTEROL CONTENT OF HEPATOCYTES FROM NORMAL AND HOMOZYGOUS FAMILIAL HYPERCHOLES-
TEROLEMIA PATIENTS 
Hepatocytes (3-5.10 5 cells/well) were incubated for 48 h in serum-free medium. After another 24 h in either serum-free medium or 
serum-free medium + 200 I-'g LDL protein/mi. cells were harvested and exhaustively extracted with chloroform/methanol (2 : I, v Iv). 
After evaporation of the organic solvent under nitrogen. cellular lipid was resuspended in isopropanol and the cholesterol was 
determined by an enzymic, fluorimetric assay before (free cholesterol) and after (total cholesterol) cholesteryl ester hydrolysis. The 
difference between total and free cholesterol is defined as esterified cholesterol. and values represent the mean ± S.E. of three normal 
cell lines. 
Cholesterol content (nmol/mg cell protein) 
total free esterfied 
Normal hepatocytes (n = 3) 
serum-free medium 127 ± 11 123 ± 10 3±3 
serum-free medium + LDL 216±15 190 ± 10 26±8 
Patient 1 
serum-free medium 116 62 54 
serum-free medium + LDL 140 80 60 
T 
! 
TABLE V 
3-HYDROXY -3-METHYLG L UT AR YL-CoA (HMG-CoA) 
REDUCTASE ACTIVITY IN HEPATOCYTES FROM 
NORMAL AND HOMOZYGOUS FAMILIAL HYPER-
CHOLESTEROLEMIA PATIENTS 
Hepatocytes (27-60 J.Lg cellular protein/well) were incubated 
in serum-free medium for 48 h followed by another 24 h in 
serum-free medium or serum-free medium with 200 p.g LDL 
protein/m!. Cells were harvested and the ability to generate 
mevalonate was determined [27]. 
Normal hepatocytes (n = 3) 
Patient 1 hepatocytes 
Patient 2 hepatocytes 
HMG-CoA reductase activity 
(pmol/mg protein/min) 
serum-free 
medium 
3.1±0.6 
4.8 
6.4 
serum-free 
medium + 
LDL 
0.6±0.2 
5.6 
6.2 
lemia hepatocytes was only 69% and 45% that of 
normal cells after LDL incubation. 
The activity of. the rate-limiting enzyme of 
cholesterol biosynthesis, 3-hydroxy-3-methyl-
glutaryl-CoA reductase, was determined in normal 
and familial hypercholesterolemia hepatocytes 
(Table V). The suppressed 3-hydroxy-3-methyl-
glutaryl-CoA reductase activity in normal hepato-
cytes was reduced by 81 % by preincubation in the 
presence of LDL. The familial hypercholestero-
lemia hepatocytes, however, did not reduce their 
3-hydroxy-3-methylglutaryl-CoA reductase activ-
ity with exposure to LDL. Therefore, the altered 
familial hypercholesterolemia hepatocyte binding 
and internalization of LDL led to a decreased 
cellular cholesterol content and increased 3-hy-
droxy-3-methylglutaryl-CoA reductase activity. 
Discussion 
The present studies were undertaken to de-
termine the effect of the loss of the LDL receptor 
pathway on cultured human hepatocyte cholesterol 
metabolism. Normal cultured human hepatocytes, 
like fibroblasts, expressed enhanced LDL binding 
and uptake with cholesterol depletion (Figs. 1 and 
4). Also, like fibroblasts, this LDL uptake led to 
cellular cholesterol accumulation (Table III) and 
an inhibition of cholesterol biosynthesis (Table 
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IV). Therefore, normal human hepatocytes share 
many of the characteristics of the LDL receptor 
pathway that have previously been defined for a 
variety of nonhepatic tissues. 
Although normal human hepatocyte LDL 
metabolism was similar to fibroblast LDL 
metabolism, homozygous familial hypercholes-
terolemia hepatocytes demonstrated differences in 
addition to similarities. Although patient 1 was 
LDL receptor-negative based on fibroblast 125 1_ 
labeled LDL uptake (Fig. 1) and acylcholester-
01: acyItransferase activity, her hepatocytes bound 
and internalized considerable quantities of 125 1_ 
labeled LDL (Fig. 4). The hepatocytes from the 
receptor-defective familial hypercholesterolemia 
homozygote (patient 2) also demonstrated a 
remarkable degree of regulatable 1251-labeled LDL 
uptake. Therefore, despite striking reductions in 
fibroblast LDL metabolism in these familial hy-
percholesterolemia subjects, a relatively high de-
gree of LDL binding by familial hypercholestero-
lemia hepatocytes was observed. Since this inter-
action was independent of fluid phase endocyto-
sis, an LDL-cell interaction is present in human 
hepatocytes which is independent of the classical 
LDL-receptor pathway. 
This LDL-receptor-independent binding differs 
from LDL-receptor binding in several ways. First, 
it is nonsaturable. As demonstrated by both 
familial hypercholesterolemia hepatocytes as well 
as normal hepatocytes, even with a constant 10-
fold excess of unlabeled LDL competing for bind-
ing, the cells which had been preincubated with 
LDL (open circles, Fig. 4) demonstrated nearly 
linear uptake with increasing 125I-Iabeled LDL 
concentration. Second, this binding was not regu-
lated. In the LDL receptor-negative subject, 
cholesterol loading by LDL preincubation and 
depletion of cellular cholesterol did not affect 
LDL uptake. Third, the non-LDL receptor bind-
ing did not lead to LDL degradation (Fig. 5) or 
effective delivery of free cholesterol to hepatocytes 
(Table IV). Although hepatocytes manifesting the 
LDL-receptor pathway increased total and free 
cellular cholesterol content by 67% and 48%, re-
spectively, the residual binding led to a free cellu-
lar cholesterol content that was less than 50% 
normal (Table IV). Finally, unlike the LDL-recep-
tor pathway which reduced the activity of the 
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Fig. 5. 12sI-labeled LDL degradation by hepatocytes from 
normal and homozygous familial hypercholesterolemia pa-
tients. The media from the normal hepatocytes (panel A), 
patient 1 hepatocytes (panel B), and from patient 2 (panel C) 
were harvested after a 6-h incubation with the indicated con-
centrations of 12sI-labeled LDL. The non-chloroform-extracta-
ble 12SI-Iabel counts in the media (trichloroacetic acid super-
natant) defined the degradation as outlined in Methods. 
Hepatocytes were incubated for 48 h prior to the exposure to 
12sr-labeled LDL in either the absence (0) or presence (e) of 2 
mg unlabeled LDL protein/m!. Values for normal hepatocytes 
represent the mean ± S.E. for five different hepatocyte prepara-
tions. 
rate-limiting enzyme for cholesterolgenesis, 3-hy-
droxy-3-methylglutaryl-CoA reductase, the resid-
ual binding did not lead to reduction in the activ-
ity of this enzyme. Therefore, the current studies 
establish that LDL-hepatocyte binding is present 
in man which is distinct from the classic fibroblast 
LDL-receptor pathway. 
A similar binding, independent of the LDL 
receptor, has been defined in other species. An 
animal model for homozygous familial hyper-
cholesterolemia is the Watanabe Heritable Hyper-
lipidemic (WHHL) rabbit. Despite the defect in 
the fibroblast LDL-receptor pathway [36], e4 C]-
sucrose LDL still accumulated in the liver to a 
normal extent, indicating an uptake process genet-
ically distinct from the LDL-receptor pathway 
[37]. Since more than 90% of this WHHL hepatic 
uptake was in hepatocytes [37J rather than Kupfer 
cells and since WHHL hepatocytes did not regu-
late 125I-labeled LDL degradation, Attie and co-
. workers concluded that the rabbit liver manifests 
an LDL uptake process independent of the classic 
LDL-receptor pathway termed the alternate path-
way [7]. 
Although the residual binding we observed 
could reflect this alternate pathway, it provides an 
inefficient means of LDL cholesterol delivery to 
the cell in vitro or it may represent other processes 
of significance to hepatocyte lipoprotein metabo-
lism. It could reflect another receptor pathway 
which partially recognizes the apolipoprotein B of 
LDL. An apparently unregulated uptake of 
apolipoprotein E-containing lipoprotein particles 
by an apoprotein recognition pathway has been 
characterized in dogs [13] and man [38), and such 
a residual pathway could explain these results in 
human hepatocytes. Another possibility revolves 
around the unique role of the hepatocyte in lipo-
protein synthesis and secretion. Nascent lipopro-
teins require transport from the Golgi to the cell 
surface. The residual ~ptake of LDL by familial 
hypercholesterolemia hepatocytes could reflect a 
recycling pathway generally used for lipoprotein 
secretion which has been unmasked in this mutant 
cell line. The residual specific LDL binding pre-
sent in hepatic membranes in these patients (Table 
III) and in previously reported cases of homo-
zygous familial hypercholesterolemia [19) could be 
explained by this latter hypothesis. 
The present observations have clinical as well 
as theoretical ramifications. Based on studies in 
the WHHL, it has recently been proposed that the 
treatment of hypercholesterolemia may be af-
fected through the modulation of hepatic LDL 
receptors [39]. The present study indicates that the 
concept of hepatic LDL receptor modulation may 
indeed have therapeutic relevance in man. In ad-
dition, the different degrees of residual LDL re-
ceptor modulation in familial hypercholestero-
lemia hepatocytes may account for the variable 
response to therapy and prognosis in this disease 
[40]. Finally, these observations lend support to 
the concept that this inborn error in lipoprotein 
metabolism may be effectively treated by liver 
transplantation. 
In conclusion, the direct study of normal and 
familial hypercholesterolemia hepatic LDL 
metabolism demonstrates that. in addition to fluid 
phase endocytosis and a regulatable LDL-receptor 
pathway, a nonsaturable LDL binding process is 
present in human hepatocytes. Although this bind-
ing could reflect an apolipoprotein B secretory 
system analogous to the mannose 6-phosphate 
T 
receptor pathway for lysosomal enzymes [41], the 
importance and physiologic role of this alternative 
recognition remains to be elucidated. 
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